Edwards Lifesciences (EW) Operating Income (2016 - 2025)
Edwards Lifesciences has reported Operating Income over the past 17 years, most recently at $151.1 million for Q4 2025.
- Quarterly results put Operating Income at $151.1 million for Q4 2025, down 51.66% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 8.3% YoY), and the annual figure for FY2025 was $1.3 billion, down 8.3%.
- Operating Income for Q4 2025 was $151.1 million at Edwards Lifesciences, down from $307.1 million in the prior quarter.
- Over the last five years, Operating Income for EW hit a ceiling of $542.1 million in Q2 2021 and a floor of $151.1 million in Q4 2025.
- Median Operating Income over the past 5 years was $370.4 million (2021), compared with a mean of $359.8 million.
- Biggest five-year swings in Operating Income: skyrocketed 419.45% in 2021 and later tumbled 51.66% in 2025.
- Edwards Lifesciences' Operating Income stood at $374.4 million in 2021, then crashed by 47.2% to $197.7 million in 2022, then skyrocketed by 75.42% to $346.8 million in 2023, then fell by 9.86% to $312.6 million in 2024, then tumbled by 51.66% to $151.1 million in 2025.
- The last three reported values for Operating Income were $151.1 million (Q4 2025), $307.1 million (Q3 2025), and $411.2 million (Q2 2025) per Business Quant data.